Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 7:11:73-103.
doi: 10.2147/LCTT.S258444. eCollection 2020.

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

Chung-Shien Lee  1   2 , Sandhya Sharma  3 , Emily Miao  4 , Cheryl Mensah  5 , Kevin Sullivan  2 , Nagashree Seetharamu  2
Affiliations
Review

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

Chung-Shien Lee et al. Lung Cancer (Auckl). .

Abstract

Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhibitors (TKIs) that target the EGFR, such as erlotinib, gefitinib, icotinib, afatinib, dacomitinib and osimertinib, have all shown to be effective in this setting. Osimertinib, a third-generation EGFR TKI, is a favorable option, but almost all patients develop resistance at some time point. There are no effective treatment options for patients who progress on osimertinib, but ongoing trials will hopefully address this unmet need. The aim of this review is to provide a comprehensive review of the data with EGFR TKIs, management of the toxicities and the ongoing trials with this class of agents.

Keywords: epidermal growth factor receptor; non-small cell lung cancer; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

Nagashree Seetharamu has served on the advisory boards for Genentech, Amgen, Takeda and Astra-Zeneca in the last year outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Epidermal growth factor receptor timeline.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590 - DOI - PubMed
    1. Toh CK, Ong WS, Lim WT, et al. A decade of never-smokers among lung cancer patients-increasing trend and improved survival. Clin Lung Cancer. 2018;19(5):e539–e550. doi: 10.1016/j.cllc.2018.03.013 - DOI - PubMed
    1. Pelosof L, Ahn C, Gao A, et al. Proportion of never-smoker non-small cell lung cancer patients at three diverse institutions. J Natl Cancer Inst. 2017;109(7):djw295. doi: 10.1093/jnci/djw295 - DOI - PMC - PubMed
    1. Pakkala S, Ramalingam SS. Epidermal growth factor receptor mutated advanced non-small cell lung cancer: a changing treatment paradigm. Hematol Oncol Clin North Am. 2017;31(1):83–99. doi: 10.1016/j.hoc.2016.08.003 - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014. Bethesda, MD: National Cancer Institute; https://seer.cancer.gov/csr/1975_2014/.